September 12, 2024 8:45 PM EDT | Source: Aion Therapeutic Inc.
Toronto, Ontario–(Newsfile Corp. – September 12, 2024) – Aion Therapeutic Inc. is providing an update on the status of its management cease trade order (MCTO) issued on August 29, 2024, by its principal regulator, the British Columbia Securities Commission (BCSC), under National Policy 12-203 Management Cease Trade Orders (NP 12-203). The Company previously announced on August 14, 2024, that it would not be able to file its annual audited consolidated financial statements for the financial year ended April 30, 2024, by the filing deadline of August 28, 2024.
Due to complexities related to the acquisition of Toppen Health, Inc. on December 15, 2023, the accounting and audit process is still ongoing. The BCSC has granted the Company an extension until October 28, 2024, to complete its 2024 Financial Disclosure, which the Company expects to meet.
There have been no material changes to the information in the Default Announcement. The Company intends to continue providing bi-weekly default status reports in compliance with NP 12-203. As of the date of this release, there are no insolvency proceedings against the Company, and no undisclosed material information regarding the Company’s affairs.
About Aion Therapeutic Inc.
Aion Therapeutic is a health and wellness business with a diverse portfolio of intellectual property, committed to innovation and transformative solutions within the industry.
Toppen, a subsidiary of Aion Therapeutic, focuses on providing advanced water filtration solutions. Their products prioritize innovation, affordability, and sustainability in meeting the global demand for clean and safe water.
DISCLAIMER & READER ADVISORY
This release contains forward-looking information and statements, subject to risks and uncertainties that may cause actual results to differ from the expressed expectations. The Company does not guarantee the accuracy of forward-looking information and does not undertake to update this information unless required by law.
Investors should note that the securities of the Company have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without proper registration or exemption. This release is for informational purposes and does not constitute an offer to sell or solicit the purchase of any securities.
The Canadian Securities Exchange does not endorse the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223111
